Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell

Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical 
Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung 
CALGARY, Feb. 8, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: 
ONC) (NASDAQ: ONCY) today announced results examining percent overall tumour 
shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous 
cell carcinoma of the lung (SCCLC) using intravenous administration of 
REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 021). 
The analysis examined percent best overall tumour changes between 
pre-treatment and up to six treatment cycles. Of 20 evaluable patients, 19 
(95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% 
shrinkage). A waterfall graph showing individual patient data will be 
available on the Company's website at 
http://www.oncolyticsbiotech.com/presentations. 
"It's exciting to have 95% of patients in this study exhibit tumour shrinkage 
and these results further suggest that REOLYSIN may have potential use in 
neoadjuvant (pre-surgical) settings," said Dr. Brad Thompson, President and 
CEO of Oncolytics. "Based on these findings we intend to continue to look at 
REOLYSIN as a treatment for cancers of the lung and cancers that metastasize 
to the lung." 
The study enrolled patients with metastatic or recurrent squamous cell 
carcinoma of the lung. The primary endpoint of the study is objective tumour 
response rates, and the secondary objectives include progression free survival 
and overall survival. To date, the Company has observed nine partial responses 
(PR), nine stable disease (SD) and three progressive disease (PD) by RECIST 
criteria for a disease control rate (complete response (CR) + PR + SD)) of 
86%. The study continues to enroll patients. 
About SCC Lung Cancer 
The American Cancer Society estimates that in 2013, approximately 228,190 new 
cases of lung cancer will be diagnosed. Approximately 84% of all lung cancers 
are classified as non-small cell lung cancer (NSCLC); squamous cell carcinomas 
account for approximately 25% of all lung cancers. Lung cancer is by far the 
leading cause of cancer death among both men and women. There will be an 
estimated 159,480 deaths from lung cancer in the United States in 2012, 
accounting for around 27% of all cancer deaths. More people die of lung cancer 
than from colon, breast, and prostate cancers combined. For more information 
about SCC lung cancer, please go to www.cancer.org. 
About Oncolytics Biotech Inc. 
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. For further information about Oncolytics, please visit: 
www.oncolyticsbiotech.com. 
This press release contains forward-looking statements within the meaning of 
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act 
of 1934, as amended, and forward-looking information within the meaning of 
Canadian securities laws. Statements, other than statements of historical 
facts, included in this press release that address activities, events or 
developments that Oncolytics expects or anticipates will or may occur in the 
future, including such things as, the Company's expectations related to the 
Phase II squamous cell carcinoma of the lung trial of REOLYSIN in combination 
with carboplatin and paclitaxel, and the Company's belief as to the potential 
of REOLYSIN as a cancer therapeutic, and other such matters are 
forward-looking statements and forward-looking information and involve known 
and unknown risks and uncertainties, which could cause the Company's actual 
results to differ materially from those in the forward-looking statements and 
forward-looking information. Such risks and uncertainties include, among 
others, risks related to the statistical sufficiency of patient enrollment 
numbers in separate patient groups, the availability of funds and resources to 
pursue research and development projects, the efficacy of REOLYSIN as a cancer 
treatment, the tolerability of REOLYSIN outside a controlled test, the success 
and timely completion of clinical studies and trials, the Company's ability to 
successfully commercialize REOLYSIN, uncertainties related to the research and 
development of pharmaceuticals and uncertainties related to the regulatory 
process. Investors should consult the Company's quarterly and annual filings 
with the Canadian and U.S. securities commissions for additional information 
on risks and uncertainties relating to the forward-looking statement and 
forward-looking information. Investors are cautioned against placing undue 
reliance on forward-looking statements and forward-looking information. The 
Company does not undertake to update these forward-looking statements and 
forward-looking information, except as required by applicable laws. 
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta, T2P 
3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@tmxequicom.com 
Dian Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 
10012 Tel: 212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com 
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2013/08/c4131.html 
CO: Oncolytics Biotech Inc.
ST: Ontario
NI: BTC NP  
-0- Feb/08/2013 11:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.